ArticleDigestive diseases and sciences2010
Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Article in Digestive diseases and sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 5 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Bisphosphonates and risk of cancers: a systematic review and meta-analysis.British journal of cancer · 2020Pooled it
- Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.BMJ open · 2015Pooled it
- The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.PloS one · 2015Pooled it
- Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013Pooled it
- Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.World journal of gastroenterology · 2012Pooled it
- Bisphosphonates as potential adjuvants for patients with cancers of the digestive system.World journal of gastroenterology · 2016Review
- Article
- Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injury.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Article
- Barrett's oesophagus: frequency and prediction of dysplasia and cancer.Best practice & research. Clinical gastroenterology · 2015Review
- Article
- Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.The American journal of gastroenterology · 2013Article
- Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012Article
- Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD).PloS one · 2012Article
- Long-term safety concerns of antiresorptive therapy.Rheumatic diseases clinics of North America · 2011Review
- Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.Current rheumatology reports · 2011Review
- Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.BMJ (Clinical research ed.) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundRecent case reports suggested a link between oral bisphosphonate use and esophageal cancer. We therefore examined the association between these medications and the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE).
designThis was a nested, matched case-control study. Cases with incident EAC at least 6 months following BE index date were matched by incidence density sampling to controls with BE without EAC. Patients with BE were found in the national Department of Veterans Affairs computerized databases, and each filled prescriptions for oral bisphosphonates between BE diagnosis and EAC diagnosis (or corresponding dates in controls). Incidence density ratios were calculated using conditional logistic regression models.
resultsIn a cohort of 11,823 patients with BE, we compared 116 cases and 696 controls. Most were men (97%). Most cases and controls had at least one filled proton pump inhibitor (PPI) prescription (95 vs. 94%, P = 0.5). Filled bisphosphonate prescriptions were very uncommon (1.7 vs. 1.9%) and were not associated with EAC; the incidence density ratio was 0.92 (95% CI, 0.21-4.15).
conclusionIn patients with BE, oral bisphosphonates were not associated with an increased risk of EAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.